Ph3 study of tarlatamab in combo with durvalumab in SCLC (DeLLphi 312)
Phase III Clinical Trial
AMG 757: 20240178 A Phase 3 Open Label Multicenter Randomized Study of First Line Tarlatamab in combination with Durvalumab Carboplatin and Etoposide versus Durvalumab Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
Participating Locations